Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P61254
UPID:
RL26_HUMAN
Alternative names:
60S ribosomal protein L26
Alternative UPACC:
P61254; B2R4F0; D3DTR8; Q02877; Q6IPY2
Background:
The Large ribosomal subunit protein uL24, also known as 60S ribosomal protein L26, is a crucial component of the large ribosomal subunit. This protein plays a pivotal role in the synthesis of proteins within the cell, a process fundamental to cellular function and growth. Its presence in the ribosome underscores its importance in translating genetic information into functional proteins.
Therapeutic significance:
Diamond-Blackfan anemia 11, a congenital non-regenerative hypoplastic anemia, is directly linked to mutations affecting the gene encoding Large ribosomal subunit protein uL24. This association highlights the protein's critical role in hematopoiesis and underscores the potential for targeted therapeutic strategies aimed at correcting the underlying genetic defects.